Skip to main content
Premium Trial:

Request an Annual Quote

Rockefeller Scientists to Genotype Island Population Using Affymetrix Arrays

NEW YORK, June 8 (GenomeWeb News) - Researchers at Rockefeller University will perform a genotyping study of a small island population to find genes associated with obesity, high blood pressure, and diabetes using Affymetrix microarrays, the company said yesterday.

 

The researchers plan to genotype more than 3,200 individuals from the Micronesian island of Kosrae, almost the entire adult population, using Affymetrix's GeneChip Mapping 100K array set. The arrays contain more than 115,000 SNPs and have been supplemented with additional SNPs for this project. The researchers plan to study 100,000 additional SNPs of relevance to the population. About half the SNPs stem from public databases, the other half from a SNP database established by Perlegen Sciences.

 

The 100K microarrays are currently available from Affymetrix under an expanded technology access program and will formally be launched this summer.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.